Orchid Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Orchid Biosciences, Inc. - overview
Established
2019
Location
San Francisco, CA, US
Primary Industry
Medical Devices & Equipment
About
Founded in 2019 and based in California, US, Orchid Biosciences, Inc. operates as a developer of medical software to detecting rare genetic disorders. The company was founded by CEO Noor Siddiqui. In April 2021, Orchid Biosciences raised USD 4.
5 million in seed funding from Refactor Capital, Village Global, Day One Ventures, Olive Capital, Boom Capital, and other investors. Orchid detects couple's future child will be at elevated or normal genetic risk to other diseases. The company allows couples to discover their future child's risk range through an at-home saliva test. If the elevated risk is detected, couples may choose their options to protect their future child's health, monitor biomarkers, adapt diet or elect for IVF.
Orchid's Embryo Report will enable couples pursuing IVF and their physicians to implant embryos in the order that mitigates disease risk.
Current Investors
Olive Capital, Stellar, Eventbrite, Inc.
Primary Industry
Medical Devices & Equipment
Sub Industries
Molecular Science, Genetics & Gene Therapy, Bioinformatics, Monitoring Equipment, Medical Software
Website
www.orchidhealth.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.